Mather, 772 patient famotidine prophylaxis PSM study: 61% lower mortality [p=0.004] and 50% lower combined mortality/intubation [p=0.003] https://c19p.org/mather
copied to clipboard
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.
|
risk of death, 61.4% lower, HR 0.39, p = 0.004, treatment 83, control 689, propensity score matching, Cox proportional hazards.
|
|
risk of death/intubation, 50.5% lower, HR 0.49, p = 0.003, treatment 83, control 689, propensity score matching, Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Mather et al., 26 Aug 2020, retrospective, USA, peer-reviewed, 3 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.